All In Biotech

Drug Trial Radar · NCT06862219

A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer

A Multicenter, Phase 4, Open-label, Single-arm, Safety Study of Enfortumab Vedotin in Adult Indian Participants With Previously Treated Locally Advanced or Metastatic Urothelial Cancer

Last checked: Nov 20, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Jun 21, 2025

Primary completion

Dec 31, 2026

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
Sponsor type
Industry
Collaborators
Pfizer
First posted
Mar 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is for Indian adults in India who have cancer in the bladder lining (urothelial cancer). Their cancer is advanced or has spread to other parts of the body. Enfortumab vedotin is a treatment for this type of cancer. The main aim of the study is to confirm the safety of enfortumab vedotin in Indian adults with urothelial cancer. During the study, people will receive enfortumab vedotin. The study treatment will be given to people slowly through a tube into a vein. This is called an infusion. People will receive 3 separate infusions of enfortumab vedotin in each 28-day (4 weeks) treatment cycle. People visit their study clinic for health-checks several times during and after they receive enfortumab vedotin.

Conditions

  • Metastatic Urothelial Carcinoma

Interventions

  • Enfortumab VedotinDrug

    Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Adverse eventsTime frame: Up to 8 months
  2. Number of participants with laboratory value abnormalities and/or AEsTime frame: Up to 7 months
  3. Number of participants with vital sign abnormalities and/or AEsTime frame: Up to 7 months
  4. Number of participants with electrocardiogram (ECG) abnormalities and/or AEsTime frame: Up to 6.5 months
  5. Number of Participants at each grade of Eastern Cooperative Oncology Group (ECOG) Performance Status scoreTime frame: Up to 7 months

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Site IN91012

    Ahmedabad, India · Recruiting

  • Site IN91010

    Bhubaneswar, India · Recruiting

  • Site IN91018

    Delhi, India · Recruiting

  • Site IN91021

    Delhi, India · Recruiting

  • Site IN91008

    Mumbai, India · Recruiting

  • Site IN91009

    Nagpur, India · Recruiting

  • Site IN91001

    Surat, India · Recruiting

  • Site IN91013

    Patna, Bihar, India · Recruiting

  • Site IN91015

    Kochi, Kerala, India · Recruiting

  • Site IN91004

    Mumbai, Maharashtra, India · Recruiting

  • Site IN91016

    New Delhi, National Capital Territory of Delhi, India · Recruiting

  • Site IN91017

    Dumas, Surat, India · Recruiting

  • Site IN91007

    Vellore, Tamil Nadu, India · Recruiting

  • Site IN91005

    Varanasi, Uttar Pradesh, India · Recruiting

  • Site IN91006

    Kolkata, West Bengal, India · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.